The Philippines is going to produce its own dosage of the anti-parasitic drug ivermectin, an official from the Department of Science and Technology (DoST) said Sunday.
In an interview with DZBB, DoST Undersecretary Rowena Guevarra said the project aims to produce its own formula of the controversial drug which some sectors believed to be a Covid-19 treatment drug.
“Our team has decided that the ivermectin formula will be done at the University of the Philippines—Manila College of Pharmacy. We will no longer buy regular formula because we will have our own dosage,” Guevarra said.
She noted that the delay in the international clinical trial on ivermectin prompted the agency to make the decision.
The Philippines is among the participants of the international clinical trial on ivermectin which was postponed due to revisions in the study protocols.
“For the ivermectin consortia, they made changes so they need to get approval from the Food and Drug Administration,” Guevarra said.
The study aims to provide data on the efficacy, safety, and effect on the viral clearance of ivermectin among asymptomatic and non-severe Covid-19 patients.
Meanwhile, the Philippines started its eight-month-long clinical trial of ivermectin drug.
The study will take place in UP Diliman, Ateneo de Manila University, De La Salle University, and Makati Science High School quarantine facilities.
“Also, we will recruit (patients) from Region 2 and Region 11. The target in patient recruitment is within October. Preliminary result is expected by end-December,” Guevarra said.